Literature DB >> 18815129

Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity.

Kenjiro Ono1, Margaret M Condron, Lap Ho, Jun Wang, Wei Zhao, Giulio M Pasinetti, David B Teplow.   

Abstract

Epidemiological evidence suggests that moderate consumption of red wine reduces the incidence of Alzheimer disease (AD). To study the protective effects of red wine, experiments recently were executed in the Tg2576 mouse model of AD. These studies showed that a commercially available grape seed polyphenolic extract, MegaNatural-AZ (MN), significantly attenuated AD-type cognitive deterioration and reduced cerebral amyloid deposition (Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., and Pasinetti, G. M. (2008) J. Neurosci. 28, 6388-6392). To elucidate the mechanistic bases for these observations, here we used CD spectroscopy, photo-induced cross-linking of unmodified proteins, thioflavin T fluorescence, size exclusion chromatography, and electron microscopy to examine the effects of MN on the assembly of the two predominant disease-related amyloid beta-protein alloforms, Abeta40 and Abeta42. We also examined the effects of MN on Abeta-induced cytotoxicity by assaying 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide metabolism and lactate dehydrogenase activity in Abeta-treated, differentiated pheochromocytoma (PC12) cells. Initial studies revealed that MN blocked Abeta fibril formation. Subsequent evaluation of the assembly stage specificity of the effect showed that MN was able to inhibit protofibril formation, pre-protofibrillar oligomerization, and initial coil --> alpha-helix/beta-sheet secondary structure transitions. Importantly, MN had protective effects in assays of cytotoxicity in which MN was mixed with Abeta prior to peptide assembly or following assembly and just prior to peptide addition to cells. These data suggest that MN is worthy of consideration as a therapeutic agent for AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815129      PMCID: PMC2583320          DOI: 10.1074/jbc.M806154200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

Review 1.  Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

2.  First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro.

Authors:  H Naiki; K Nakakuki
Journal:  Lab Invest       Date:  1996-02       Impact factor: 5.662

3.  Wine consumption in the elderly.

Authors:  L Letenneur; J F Dartigues; J M Orgogozo
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

4.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  Wine, alcohol, platelets, and the French paradox for coronary heart disease.

Authors:  S Renaud; M de Lorgeril
Journal:  Lancet       Date:  1992-06-20       Impact factor: 79.321

7.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state.

Authors:  C J Pike; D Burdick; A J Walencewicz; C G Glabe; C W Cotman
Journal:  J Neurosci       Date:  1993-04       Impact factor: 6.167

Review 8.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

Authors:  J Hardy; D Allsop
Journal:  Trends Pharmacol Sci       Date:  1991-10       Impact factor: 14.819

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

10.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Authors:  K C Evans; E P Berger; C G Cho; K H Weisgraber; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more
  60 in total

Review 1.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 3.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 4.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

5.  Effects of Congo red on aβ(1-40) fibril formation process and morphology.

Authors:  Partha Pratim Bose; Urmimala Chatterjee; Ling Xie; Jan Johansson; Emmanuelle Göthelid; Per I Arvidsson
Journal:  ACS Chem Neurosci       Date:  2010-02-03       Impact factor: 4.418

6.  Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity.

Authors:  Lap Ho; Danyue Zhao; Kenjiro Ono; Kai Ruan; Ilaria Mogno; Mayumi Tsuji; Eileen Carry; Justin Brathwaite; Steven Sims; Tal Frolinger; Susan Westfall; Paolo Mazzola; Qingli Wu; Ke Hao; Thomas E Lloyd; James E Simon; Jeremiah Faith; Giulio M Pasinetti
Journal:  J Nutr Biochem       Date:  2018-11-14       Impact factor: 6.048

7.  Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.

Authors:  Jason Pitt; William Roth; Pascale Lacor; Amos B Smith; Matthew Blankenship; Pauline Velasco; Fernanda De Felice; Paul Breslin; William L Klein
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-23       Impact factor: 4.219

8.  Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β.

Authors:  Ali Reza A Ladiwala; Mauricio Mora-Pale; Jason C Lin; Shyam Sundhar Bale; Zachary S Fishman; Jonathan S Dordick; Peter M Tessier
Journal:  Chembiochem       Date:  2011-06-10       Impact factor: 3.164

Review 9.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy.

Authors:  Cathie M Pfleger; Jun Wang; Lauren Friedman; Roselle Vittorino; Lindsay M Conley; Lap Ho; Hayley C Fivecoat; Giulio M Pasinetti
Journal:  Int J Alzheimers Dis       Date:  2010-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.